2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1222

A Systematic Review of Consumer Perceived Health Service Needs Related to Osteoarthritis

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1063

A Systematic Review of Direct Oral Anticoagulant Use in Antiphospholipid Syndrome

Antiphospholipid Syndrome - Poster I

9:00AM-11:00AM: Abstract Number: 1169

A Systematic Review of Rheumatic Disease Epidemiology in the Indigenous Populations of Canada, the United States, Australia and New Zealand

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1443

A Therapeutic Peptide Vaccine Reduces Pro-Inflammatory Responses and Suppresses Arthritis in the Cartilage Proteoglycan G1 Domain-Induced Mouse Model of Rheumatoid Arthritis

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1560

A Unique Immune Signature in Patients with Active Rheumatoid Arthritis but Normal C-Reactive Protein Levels: Potential for New Therapeutic Targets?

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 1196

AA Amyloidosis: An Evaluation of Epidemiology and Prevalence in the US and EU5 Countries

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1612

Abatacept Targets T Follicular Helper Cells in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1715

ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A, Does Not Provide Significantly Greater Efficacy Compared with Adalimumab in Subjects with Psoriatic Arthritis: Results from Exposure-Response Analyses

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1424

Acceptability of a Connected Activity Tracker in 92 Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA): A 3-Months Study

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1414

Access to an Active, Interactive Self-Assessment e-Health Platform Improves Patient-Physician Communication in Rheumatoid Arthritis: Results of a Randomized Controlled Trial Including 320 Patients over 1 Year

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1248

Access to Care: The Patient Perspective from the 2015 ACR/ARHP Workforce Study

Healthcare Disparities in Rheumatology - Poster II

9:00AM-11:00AM: Abstract Number: 1790

Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1923

Activated Partial Thromboplastin Time Reflects Disease Activity in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1860

Activating Transcription Factor 3 – a New Linkage Between Vasculopathy and Organ Fibrosis in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster II

9:00AM-11:00AM: Abstract Number: 1101

Adalimumab:TNF Complexes Induce a Divergent Proteomic Profile in Human Osteoclast Precursors to That Resembling a Monocytic Cell

Biology and Pathology of Bone and Joint - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].